Loading

Welcome to my Home Page!

    To Japanese pages

    To German pages

    Links/Blogs

Translation Samples

Want to observe acupuncture in Japan? Take a look here 

 

"It is my job to ensure, that patients do NOT NEED to see me ..."

 

I can also be found on some blogs (not all are shown here), but not everything is in English.

      

Loratadine

"Loratadine 10mg with visa, allergy shots or sublingual."

By: Jonathan Handy

  • Consultant in Intensive Care Medicine,Royal Marsden Hospital,Honorary Senior Lecturer,Imperial College London

Examples of subjective information include patient-provided information about disease symptoms allergy testing veterinary buy cheap loratadine 10 mg on line, over-the-counter medications allergy diagnosis buy 10mg loratadine visa, drug allergy descriptions allergy symptoms 5 dpo loratadine 10 mg without prescription, and compliance allergy symptoms guinea pig purchase loratadine 10mg free shipping. The second paragraph begins with "O:" and contains objective information obtained by physically examining the patient, reviewing laboratory data, checking prescription records for doses and refill patterns, locating medication costs from a printed or online formulary, and so on. Some information can be either subjective or objective, depending on how it is obtained. The most important thing to remember when composing the subjective and objective portions of notes is that only information pertaining directly to the assessment should be included. If the subjective and objective paragraphs are written well, the problem should be obvious to the reader. Other types of information included in the assessment paragraph are the therapeutic goals and a brief discussion of the therapeutic alternatives. The fourth paragraph begins with either "P:" or "R:" and details either a plan (P) or a recommendation (R), whichever is more appropriate for the situation. Also, the monitoring plan must be detailed, including specifically what should be measured. A backup plan for use in the event of therapeutic failure should also be noted here. Finally, instructions for the proper use of prescribed medication or medications should be included to enhance the therapeutic outcome. Ansel, the originator of this textbook, whose guidance and hard work over the years have significantly contributed to the education of tens of thousands of pharmacists worldwide. Popovich for his extensive contribution to this textbook on clinical pharmacy and pharmacy practice and for his unique ability to present the integrated approach used in this book. Together, we extend our gratitude to the students and academic colleagues who have shared their thoughts with us on this revision; we hope that we have been successful in responding to their thoughtful suggestions. We also acknowledge with appreciation our colleagues in industry who have generously provided scientific and technical information and updated the figures and photos for our use. We gratefully acknowledge the following individuals who contributed to the development of this book through their critiques, reviews, and suggestions on the individual chapters. Chapter 15 (Parenterals): Mary Baker, PharmD, Medical Manager and Clinical Fellow, Global Medical Affairs, Hospira, Inc. Smith, PharmD, Clinical Assistant Professor, University of Illinois at Chicago, College of Pharmacy and Clinical Pharmacist, Ambulatory Care Services, University of Illinois at Chicago, College of Pharmacy. A number of former doctoral students at the Purdue University School of Pharmacy and the University of Illinois at Chicago, College of Pharmacy helped conceive them, and we sincerely appreciate their contributions to this book. Compare and contrast significant drug regulation and control federal laws and their impact on pharmacy 4. Summarize the Code of Ethics for Pharmacists of the American Pharmacists Association 6. One of the most astounding qualities of drugs is the diversity of their actions and effects on the body. This quality enables their selective use in the treatment of a range of common and rare conditions involving virtually every body organ, tissue, and cell. Some drugs selectively stimulate the cardiac muscle, the central nervous system, or the gastrointestinal tract, whereas other drugs have the opposite effect. Mydriatic drugs dilate the pupil of the eye, and miotics constrict or diminish pupillary size. Drugs can render blood more coagulable or less coagulable; they can increase the hemoglobin content of the erythrocytes, reduce serum cholesterol, or expand blood volume. Diuretic drugs increase the flow of urine; expectorant drugs increase respiratory tract fluid; and cathartics or laxatives evacuate the bowel. Other drugs decrease the flow of urine, diminish body secretions, or induce constipation. Drugs may be used to reduce pain, fever, thyroid activity, rhinitis, insomnia, gastric acidity, motion sickness, blood pressure, and mental depression.

cheap loratadine 10mg otc

Taking medicines to allergy symptoms coughing at night buy cheap loratadine 10 mg line help lower the risk of getting a disease is called chemoprevention allergy kid meme loratadine 10mg with mastercard. The most commonly used medicines to do i need allergy shots quiz buy cheap loratadine 10mg online lower breast cancer risk are tamoxifen and raloxifene allergy forecast map discount 10mg loratadine free shipping. Other medicines called aromatase inhibitors (such as anastrozole and exemestane) might also be options. The first step in deciding if you should take a drug to help lower your chances of getting breast cancer is to have a health care provider assess your breast cancer risk. Most experts say that your breast cancer risk should be higher than average for you to consider taking one of these drugs. If you do have a higher than average risk, you need to compare the benefit of possibly reducing your chance of getting breast cancer with the risk of side effects and other problems from taking one of these drugs. Your risk factors need to be identified to find out if you are at higher than average risk for breast cancer. But keep in mind that having risk factors that are linked to a higher risk does not mean that you will definitely develop breast cancer. In fact, most women who have one or more risk factors never develop breast cancer. Some important risk factors for breast cancer include: q Getting older 31 American Cancer Society cancer. The Breast Cancer Risk Assessment Tool5 (based on the modified Gail Model) is commonly used to assess this risk. It can estimate your risk of getting breast cancer in the next 5 years and over your lifetime, based on many of the factors listed above. For instance, it only looks at family history in close relatives (like siblings, parents, and children). Other risk assessment tools, such as the Tyrer-Cuzick model and the Claus model, are based largely on family history. The American Cancer Society does not have recommendations for the use of medicines to help lower the risk of breast cancer. Are there reasons not to take one of these drugs to help reduce breast cancer risk? All drugs have risks and side effects that must be discussed when making the decision about chemoprevention. Women with any of these conditions should talk to their doctors to see if the benefits of taking one of these drugs would outweigh the risks. A woman who has been diagnosed with any type of uterine cancer or atypical hyperplasia of the uterus (a kind of pre-cancer) should not take tamoxifen to help lower breast cancer risk. Raloxifene has not been tested in pre-menopausal women, so it should only be used if you have gone through menopause. Aromatase inhibitors are not useful for pre-menopausal women, so they should only be used if you have gone through menopause. Talk with your doctor about your total health picture to make the best possible choice for you. To learn more about the use of these medicines for chemoprevention, see: q q Tamoxifen and Raloxifene for Lowering Breast Cancer Risk Aromatase Inhibitors for Lowering Breast Cancer Risk Hyperlinks 1. Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. Medication use for the risk reduction of primary breast cancer in women: Updated evidence report and systematic 34 American Cancer Society cancer. Last Medical Review: September 10, 2019 Last Revised: September 10, 2019 Tamoxifen and Raloxifene for Lowering Breast Cancer Risk Tamoxifen and raloxifene have been shown to reduce the risk of breast cancer in women with a higher than average risk, but these drugs can have their own risks and side effects. This means that they act against (or block) estrogen (a female hormone) in some tissues of the body, but act like estrogen in others. Both of these drugs block estrogen in breast cells, which is why they can be useful in lowering breast cancer risk. Raloxifene is used mostly to prevent and treat osteoporosis (very weak bones) in post-menopausal women. Tamoxifen can be taken whether or not you have gone through menopause, but raloxifene is only approved for post-menopausal women. When the results of all the studies are taken together, the overall reduction in risk for these drugs is about 40% (more than a third).

Cheap loratadine 10mg otc. Causes Symptoms and Treatment of Food allergies.

buy discount loratadine 10mg line

These patients are often inappropriately treated for cellulitis with antibiotics for several weeks to allergy forecast san antonio order loratadine 10 mg otc months allergy medicine non antihistamine buy cheap loratadine 10mg line. Because of the aggressive nature of this disease allergy forecast nyc mold cheap loratadine 10mg on-line, a delay in diagnosis can be fatal for some of these women allergy symptoms on kids generic loratadine 10mg visa. The natural history of locally advanced breast cancer shows that even when local-regional control is accomplished, systemic relapse and death from breast cancer eventually occur in most patients if systemic therapy is not utilized. Other potential benefits related 2254 to early initiation of systemic therapy include delivery of drugs through an intact vasculature, in vivo assessment of response to therapy, and the opportunity to study the biologic effects of the systemic treatment. However, this approach to therapy also results in a loss of standard, well-validated pathologic prognostic markers, such as initial tumor size (measured by pathologic examination) and the number of axillary lymph nodes involved. However, in light of other benefits gained with neoadjuvant therapy, these two factors may not be enough to continue to drive the practice of primary surgery. The topic of adjuvant versus neoadjuvant systemic therapy is fraught with controversy, but the many advantages of neoadjuvant, primary systemic therapy are continuing to drive an increase in the number of operable patients offered this treatment modality. The chemotherapy regimens used in this setting are similar to those used in the adjuvant setting, but the regimens usually include an anthracycline, incorporate a taxane in some manner, and may have higher dose density or dose intensity. Adjuvant radiation therapy should be administered to all locally advanced breast cancer patients to minimize local recurrences, regardless of the type of surgery used for that individual patient. Inoperable tumors that are unresponsive to systemic chemotherapy may require radiation therapy for local management and may not be eligible for surgical resection after radiation. For most patients in this category, cure is still the primary goal of therapy and can be achieved in a large number of patients when all treatment modalities are employed. The most important factor predicting response to endocrine therapy is the presence of estrogen and progesterone receptors in the primary tumor tissue. Thus the most important factor determining choice of endocrine versus cytotoxic chemotherapy is the presence of hormone receptors in the primary breast tumor. Site of disease is also important because endocrine therapy is more likely to be effective in patients with bone and soft-tissue metastases. Patients with symptomatic visceral and/or central nervous system involvement generally have more rapidly growing cancers that require chemotherapy. Endocrine therapy is the treatment of choice for patients with hormone receptor-positive tumors who exhibit the first sign of metastatic disease in soft tissue, bone, or pleura, because of the equal probability of response to hormonal therapy as compared to chemotherapy, and a preferable toxicity profile with endocrine therapy. Patients who respond to initial endocrine therapy often respond to a second (or even third) hormonal manipulation. But the response rate is lower and duration of response is shorter with second (and third) hormonal manipulations. Patients are sequentially treated with endocrine therapy until their tumors cease to respond or the patient ceases to benefit from endocrine therapy, at which time cytotoxic chemotherapy can be administered. Concurrent administration of different hormonal therapies or chemotherapy plus hormones is generally not used in the setting of metastatic breast cancer because of lack of increased efficacy and evidence of increased toxicity. Women with hormone receptor-negative tumors, with rapidly progressive or symptomatic lung, liver, or bone marrow involvement, and those with progressive disease while on initial endocrine therapy are usually treated initially with cytotoxic chemotherapy. All breast cancer patients with metastases to the bone should be considered for treatment with an intravenous bisphosphonate. After it has advanced beyond local­ regional disease, breast cancer is currently incurable. However, some patients live for many years with metastatic disease, making this a chronic disease requiring long-term management strategies that incorporate improvements and/or maintenance of quality of life. The goals of treatment of metastatic breast cancer are to improve symptoms and quality-of-life and extend survival. Thus it is important to choose therapy with optimal activity while minimizing toxicities. Treatment of metastatic breast cancer with cytotoxic, biologic, or endocrine therapy often results in regression of disease and improvements in quality-of-life. The choice of therapy for metastatic disease is based on the site of disease involvement and Endocrine Therapy the pharmacologic goal of endocrine therapy for breast cancer is to either (a) decrease circulating levels of estrogen or (b) prevent the effects of estrogen at the breast cancer cell (targeted therapy) by blocking the hormone receptors or downregulating the presence of those receptors. Achievement of the first goal depends on the menopausal status of the patient, but achievement of the second goal is independent of menopausal status. Many endocrine therapies are available to target either goal of therapy, and combinations of drugs with different mechanisms of action have also been investigated. Unfortunately, most combinations have not demonstrated any efficacy benefits over single-agent hormone therapy, but have increased toxicity.

cheap 10mg loratadine with visa

However allergy shots japan buy loratadine 10mg without a prescription, when conversion is necessary or desired allergy kaiser buy loratadine 10 mg cheap, it is a simple matter of selecting and applying the appropriate intersystem conversion factor allergy medication for dogs buy 10 mg loratadine with visa. For example allergy treatment xanthelasma cheap 10 mg loratadine with amex, if one wishes to determine the number of milliliters in 8 f, the conversion factor that most directly relates milliliters and fluidounces is selected. Another example: How many 30-mL containers may be filled from 10 gal of a formulation? By dividing this total number of milliliters by 30, the number of containers that may be filled is found to be 1,261. Since by definition percentage strength is in parts per hundred, just determine how many grams of the drug are present in each 100 mL solution. In w/v problems, the specific gravity of the preparation is assumed to be the same as that of water (sp. Therefore, in the problem example, the 400 mL is assumed to weigh 400 g, and 5% of 400 g = 20 g, the amount of drug needed. A w/w problem example: How many grams of zinc oxide powder should be used in preparing 120 g of a 20% w/w ointment? Ratio strength is sometimes used to express the strength of or to calculate the amount of a component needed to make a relatively dilute preparation. Ratio strength expressions use the w/v, v/v, and w/w designations in the same manner as percentage strength expressions. For example: A 1:1000 w/v preparation of a solid constituent in a liquid preparation = 1 g of the solid constituent in 1,000 mL of preparation. A 1:1000 v/v preparation of a liquid constituent in a liquid preparation = 1 mL of the constituent in 1,000 mL of preparation. A 1:1000 w/w preparation of a solid constituent in a solid or semisolid preparation = 1 g of the constituent in 1,000 g of preparation. A ratio strength calculation: What is the ratio strength of 6,000 mL of solution containing 3 g of drug? In this example, if 3 g of drug is in 6,000 mL of solution, 1 g of drug is contained in 2,000 mL, and thus the ratio strength is 1:2,000 w/v. Sometimes the answers do not come out as evenly; for example, what is the ratio strength of 0. Another ratio strength calculation: In grams, how much drug is needed to make 5 L of a 1:400 w/v solution? By definition (of 1:400 w/v), 1 g of drug is needed for each 400 mL of the solution. Since 5 L, or 5,000 mL, of solution is to be prepared, the amount of drug required is found by solving 1 g/400 mL = (Ч) g/5,000 mL, or 12. Rather than being expressed in terms of percentage strength or ratio strength, the strength of some pharmaceutical preparations, particularly injections and sometimes oral liquids, is based on drug content per unit of volume, as milligrams per milliliter. Thus, flexibility in dosing can be achieved by administering the volume of preparation that contains the desired dose. A standard manufacturing formulation, or master formula, contains the quantitative amounts of each ingredient needed to prepare a specified quantity of product. When preparing other quantities, larger or smaller, the quantitative relationship of each component to the other in the formula must be maintained. For example, if there is 2 g of ingredient A and 10 mL of ingredient B (among other ingredients) in a formula for 1,000 mL, one must use 0. If, on the other hand, a formula is to be enlarged-for example, from 1 L (1,000 mL) of product to a gallon (3,785 mL)-the amount of each ingredient required is 3. In these examples, the quantity of product prepared is reduced or enlarged, but the quantitative relationship between each ingredient and the product strength remains unchanged. Solid dosage forms, such as tablets and capsules, are generally prepared in various strengths to allow flexibility in dosing. The desired dose for a drug prepared in a liquid form may be provided by the volume administered. For example, if a liquid dosage form contains 5 mg of drug per milliliter and if a dose of 25 mg of drug is desired, 5 mL of the liquid may be administered. Commercially manufactured products are formulated to provide the drug in dosage forms and amounts convenient for administration. When the desired dosage or dosage form is commercially unavailable, the pharmacist may be called upon to compound the desired preparation. Although the household teaspoon may vary in volume capacity from approximately 3 to 8 mL, the American Standard Teaspoon has been established as having a volume of 4.

References:

  • https://journalofethics.ama-assn.org/sites/journalofethics.ama-assn.org/files/2018-06/vm-0709.pdf
  • https://www.oecd-ilibrary.org/e-health_5jlwt548xl9p.pdf?itemId=%2Fcontent%2Fcomponent%2F9789264251823-14-en&mimeType=pdf
  • https://haitiortho.files.wordpress.com/2016/11/2014-oite-study-guide.pdf
  • https://www.norlandrx.com/doc/LDN-Patient-4-Pager-1-19-Norland.pdf
  • https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202192s017lbl.pdf